SOPHiA GENETICS has announced the launch of SOPHiA DDM™ Digital Twins, an AI-powered technology designed to enhance intelligent decision-making in oncology. The Digital Twins platform creates dynamic virtual representations of individual patients using clinical, biological, imaging, and genomic data, enabling oncologists to simulate treatment responses and disease trajectories in real time. The technology aims to help match patients with the most effective therapies, reduce exposure to ineffective treatments, and improve precision medicine in cancer care. The announcement states that Digital Twins is launching for lung cancer on the SOPHiA DDM™ Platform, with additional cancer types to follow. These results and the new platform will be presented at the ESMO conference in Berlin, Germany, from October 17 to 21.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NE99202) on October 16, 2025, and is solely responsible for the information contained therein.
Comments